{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:32:32Z","timestamp":1787963552541,"version":"build-2784847793"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Pediatr"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s12098-018-02854-8","type":"journal-article","created":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T06:33:08Z","timestamp":1549002788000},"page":"725-731","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Newer Drugs for Tuberculosis Prevention and Treatment in Children"],"prefix":"10.1007","volume":"86","author":[{"given":"Ben J.","family":"Marais","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,1]]},"reference":[{"key":"2854_CR1","unstructured":"Global tuberculosis report 2017. World Health Organization, Geneva, Switzerland. Available at: \n                    www.who.int\/tb\/publications\/global_report\/en\/\n                    \n                  . Accessed 6th September 2018."},{"key":"2854_CR2","doi-asserted-by":"crossref","unstructured":"Jenkins HE, Yuen CM, Rodriguez CA, et al. Mortality in children diagnosed with tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2017;17:285\u201395.","DOI":"10.1016\/S1473-3099(16)30474-1"},{"key":"2854_CR3","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1016\/S0140-6736(14)60420-7","volume":"383","author":"SM Graham","year":"2014","unstructured":"Graham SM, Sismandis C, Menzies HJ, Marais BJ, Detjen AK, Black RE. Importance of tuberculosis to address child survival. Lancet. 2014;383:1605\u20137.","journal-title":"Lancet"},{"key":"2854_CR4","doi-asserted-by":"publisher","first-page":"e898","DOI":"10.1016\/S2214-109X(17)30289-9","volume":"5","author":"PJ Dodd","year":"2017","unstructured":"Dodd PJ, Yuen CM, Sismanidis C, Seddon JA, Jenkins HE. The global burden of tuberculosis mortality in children: a mathematical modelling study. Lancet Glob Health. 2017;5:e898\u2013906.","journal-title":"Lancet Glob Health"},{"key":"2854_CR5","doi-asserted-by":"crossref","unstructured":"Jenkins HE, Tolman AW, Yuen CM, et al. Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates. Lancet. 2014;383:1572\u20139.","DOI":"10.1016\/S0140-6736(14)60195-1"},{"key":"2854_CR6","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/S1473-3099(16)30132-3","volume":"16","author":"PJ Dodd","year":"2016","unstructured":"Dodd PJ, Sismanidis C, Seddon JA. Global burden of drug-resistant tuberculosis in children: a mathematical modelling study. Lancet Infect Dis. 2016;16:1193\u2013201.","journal-title":"Lancet Infect Dis"},{"key":"2854_CR7","unstructured":"Harausz EP, Garcia-Prats AJ, Law S, et al. Treatment and outcomes in children with multidrug-resistant tuberculosis: a systematic review and individual patient data meta-analysis. PLoS Med. 2018;15:e1002591."},{"key":"2854_CR8","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ijid.2016.11.006","volume":"56","author":"GJ Fox","year":"2017","unstructured":"Fox GJ, Dobler C, Marais BJ, Denholm J. Preventive therapy for latent tuberculosis infection \u2013 the promise and challenges. Int J Infect Dis. 2017;56:68\u201376.","journal-title":"Int J Infect Dis"},{"key":"2854_CR9","first-page":"935","volume":"95","author":"GW Comstock","year":"1967","unstructured":"Comstock GW, Ferebee SH, Hammes LM. A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis. 1967;95:935\u201343.","journal-title":"Am Rev Respir Dis"},{"key":"2854_CR10","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1164\/rccm.201412-2173LE","volume":"191","author":"RA Accinelli","year":"2015","unstructured":"Accinelli RA, Romero LR, Garc\u00eda RF, S\u00e1nchez R. Sustained benefit of community-based tuberculosis interventions after 30 years. Am J Respir Crit Care Med. 2015;191:1202\u20133.","journal-title":"Am J Respir Crit Care Med"},{"key":"2854_CR11","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ijid.2016.12.015","volume":"56","author":"BJ Marais","year":"2017","unstructured":"Marais BJ. Improving access to tuberculosis preventive therapy and treatment for children. Int J Infect Dis. 2017;56:122\u20135.","journal-title":"Int J Infect Dis"},{"key":"2854_CR12","doi-asserted-by":"publisher","first-page":"S74","DOI":"10.1016\/S0163-4453(17)30195-0","volume":"74","author":"CM Perez-Velez","year":"2017","unstructured":"Perez-Velez CM, Roya-Pabon CL, Marais BJ. A systematic approach to diagnosing intra-thoracic tuberculosis in children. J Infect. 2017;74:S74\u201383.","journal-title":"J Infect"},{"key":"2854_CR13","unstructured":"Latent TB Infection: Updated and consolidated guidelines for programmatic management 2018. World Health Organization, Geneva, Switzerland Available at: \n                    www.whoint\/tb\/publications\/2018\/latent-tuberculosis-infection\/en\n                    \n                  \/. Accessed 6th September 2018."},{"key":"2854_CR14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1164\/ajrccm\/145.1.36","volume":"145","author":"Hong Kong Chest Service","year":"1992","unstructured":"Hong Kong Chest Service. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong chest service\/tuberculosis research Centre, Madras\/British Medical Research Council. Am Rev Respir Dis. 1992;145:36\u201341.","journal-title":"Am Rev Respir Dis"},{"key":"2854_CR15","doi-asserted-by":"crossref","unstructured":"Menzies D, Long R, Trajman A, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med. 2008;149:689\u201397.","DOI":"10.7326\/0003-4819-149-10-200811180-00003"},{"key":"2854_CR16","doi-asserted-by":"crossref","unstructured":"Sharma SK, Sharma A, Kadhiravan T, Tharyan P. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Cochrane Database Syst Rev. 2013;7:CD007545.","DOI":"10.1002\/14651858.CD007545.pub2"},{"key":"2854_CR17","doi-asserted-by":"crossref","unstructured":"Menzies D, Adjobimey M, Ruslami R, et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med. 2018;379:440\u201353.","DOI":"10.1056\/NEJMoa1714283"},{"key":"2854_CR18","doi-asserted-by":"crossref","unstructured":"Diallo T, Adjobimey M, Ruslami R, et al. Safety and side effects of rifampin versus isoniazid in children. N Engl J Med. 2018;379:454\u201363.","DOI":"10.1056\/NEJMoa1714284"},{"key":"2854_CR19","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1086\/427802","volume":"40","author":"J Ena","year":"2005","unstructured":"Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis. 2005;40:670\u20136.","journal-title":"Clin Infect Dis"},{"key":"2854_CR20","doi-asserted-by":"crossref","unstructured":"Spyridis NP, Spyridis PG, Gelesme A, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis. 2007;45:715\u201322.","DOI":"10.1086\/520983"},{"key":"2854_CR21","doi-asserted-by":"crossref","unstructured":"Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365:2155\u201366.","DOI":"10.1056\/NEJMoa1104875"},{"key":"2854_CR22","doi-asserted-by":"crossref","unstructured":"Sterling TR, Scott NA, Miro JM, et al. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. AIDS. 2016;30:1607\u201315.","DOI":"10.1097\/QAD.0000000000001098"},{"key":"2854_CR23","doi-asserted-by":"crossref","unstructured":"Villarino ME, Scott NA, Weis SE, et al; International maternal pediatric and adolescents AIDS Clinical Trials Group; tuberculosis trials consortium. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. JAMA Pediatr. 2015;169:247\u201355.","DOI":"10.1001\/jamapediatrics.2014.3158"},{"key":"2854_CR24","doi-asserted-by":"crossref","unstructured":"Pease C, Hutton B, Yazdi F, et al. Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses. BMC Infect Dis. 2017;17:265.","DOI":"10.1186\/s12879-017-2377-x"},{"key":"2854_CR25","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/cid\/ciy230","volume":"67","author":"KT Johnson","year":"2018","unstructured":"Johnson KT, Churchyard GJ, Sohn H, Dowdy DW. Cost-effectiveness of preventive therapy for tuberculosis with isoniazid and rifapentine versus isoniazid alone in high-burden settings. Clin Infect Dis. 2018;67:1072\u20138.","journal-title":"Clin Infect Dis"},{"key":"2854_CR26","doi-asserted-by":"crossref","unstructured":"Jindani A, Harrison TS, Nunn AJ, et al. RIFAQUIN trial Team.High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med. 2014;371:1599\u2013608.","DOI":"10.1056\/NEJMoa1314210"},{"key":"2854_CR27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0140-6736(10)61972-1","volume":"377","author":"M Becerra","year":"2011","unstructured":"Becerra M, Appleton S, Franke M, et al. Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet. 2011;377:147\u201352.","journal-title":"Lancet"},{"key":"2854_CR28","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1183\/09031936.00070812","volume":"41","author":"GJ Fox","year":"2013","unstructured":"Fox GJ, Barry SE, Britton WJ, Marks GB. Contact investigation for tuberculosis: a systematic review and meta-analysis. Eur Resp J. 2013;41:140\u201356.","journal-title":"Eur Resp J"},{"key":"2854_CR29","doi-asserted-by":"crossref","unstructured":"Bamrah S, Brostrom R, Dorina F, et al. Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012. Tuberc Lung Dis. 2014;18:912\u20138.","DOI":"10.5588\/ijtld.13.0028"},{"key":"2854_CR30","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1542\/peds.109.5.765","volume":"109","author":"HS Schaaf","year":"2002","unstructured":"Schaaf HS, Gie RP, Kennedy M, Beyers N, Hesseling PB, Donald PR. Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up. Pediatrics. 2002;109:765\u201371.","journal-title":"Pediatrics"},{"key":"2854_CR31","doi-asserted-by":"crossref","unstructured":"Harausz EP, Garcia-Prats AJ, Seddon JA, et al. Sentinel project on pediatric drug-resistant tuberculosis. New and repurposed drugs for pediatric multidrug-resistant tuberculosis. Practice-based recommendations. Am J Respir Crit Care Med. 2017;195:1300\u201310.","DOI":"10.1164\/rccm.201606-1227CI"},{"key":"2854_CR32","doi-asserted-by":"crossref","unstructured":"Diacon AH, Pym A, Grobusch MP, et al; TMC207-C208 study group. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014;371:723\u201332.","DOI":"10.1056\/NEJMoa1313865"},{"key":"2854_CR33","unstructured":"Rapid Communication: Key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR\/RR-TB).WHO, Geneva, Switzerland. Available at: \n                    www.who.int\/tb\/publications\/2018\/rapid_communications_MDR\/en\n                    \n                  . Accessed 6th September 2018."},{"key":"2854_CR34","doi-asserted-by":"crossref","unstructured":"Seddon JA, Schaaf HS, Marais BJ, et al. Time to act on injectable-free regimens for children with multidrug-resistant tuberculosis: time to act. Lancet Respir Med. 2018;6:662\u20136.","DOI":"10.1016\/S2213-2600(18)30329-1"},{"key":"2854_CR35","doi-asserted-by":"crossref","unstructured":"Lewis JM, Hine P, Walker J, et al. First experience of effectiveness and safety of bedaquiline for 18 months within an optimised regimen for XDR-TB. Eur Respir J. 2016;47:1581\u20134.","DOI":"10.1183\/13993003.01980-2015"},{"key":"2854_CR36","doi-asserted-by":"publisher","first-page":"6406","DOI":"10.1128\/AAC.03246-14","volume":"58","author":"EM Svensson","year":"2014","unstructured":"Svensson EM, Dooley KE, Karlsson MO. Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection. Antimicrob Agents Chemother. 2014;58:6406\u201312.","journal-title":"Antimicrob Agents Chemother"},{"key":"2854_CR37","doi-asserted-by":"crossref","unstructured":"Pandie M, Wiesner L, McIlleron H, et al. Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir\/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB. J Antimicrob Chemother. 2016;71:1037\u201340.","DOI":"10.1093\/jac\/dkv447"},{"key":"2854_CR38","doi-asserted-by":"crossref","unstructured":"Liu Y, Matsumoto M, Ishida H, et al. Delamanid: from discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB). Tuberculosis. 2018;111:20\u201330.","DOI":"10.1016\/j.tube.2018.04.008"},{"key":"2854_CR39","unstructured":"The use of delamanid in the treatment of multidrug-resistant tuberculosis in children and adolescents: Interim policy guidance. WHO, Geneva,Switzerland. Available at: \n                    www.apps.who.int\/iris\/bitstream\/10665\/250614\/1\/9789241549899-eng.pdf\n                    \n                  . Accessed 6th September 2018."},{"key":"2854_CR40","doi-asserted-by":"crossref","unstructured":"Lach\u00e2tre M, Rioux C, D\u00fb DL, et al. Bedaquiline plus delamanid for XDR tuberculosis. Lancet Infect Dis. 2016;16:294.","DOI":"10.1016\/S1473-3099(16)00047-5"},{"key":"2854_CR41","doi-asserted-by":"crossref","unstructured":"Tadolini M, Lingtsang RD, Tiberi S, et al. Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine. Eur Respir J. 2016;48:1527\u20139.","DOI":"10.1183\/13993003.01552-2016"},{"key":"2854_CR42","doi-asserted-by":"crossref","unstructured":"Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med. 2012;367:1508\u201318.","DOI":"10.1056\/NEJMoa1201964"},{"key":"2854_CR43","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.tube.2013.10.003","volume":"94","author":"AJ Garcia-Prats","year":"2014","unstructured":"Garcia-Prats AJ, Rose PC, Hesseling AC, Schaaf HS. Linezolid for the treatment of drug-resistant tuberculosis in children: a review and recommendations. Tuberculosis. 2014;94:93\u2013104.","journal-title":"Tuberculosis"},{"key":"2854_CR44","doi-asserted-by":"crossref","unstructured":"Tang S, Yao L, Hao X, et al. Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized control study in China. Clin Infect Dis. 2015;60:1361\u20137.","DOI":"10.1183\/13993003.congress-2015.PA3330"},{"key":"2854_CR45","doi-asserted-by":"crossref","unstructured":"Kroger A, Pannikar V, Htoon MT, et al. International open trial of uniform multi-drug therapy regimen for 6 months for all types of leprosy patients: rationale, design and preliminary results. Tropical Med Int Health. 2008;13:594\u2013602.","DOI":"10.1111\/j.1365-3156.2008.02045.x"}],"container-title":["The Indian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12098-018-02854-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12098-018-02854-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12098-018-02854-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:31:43Z","timestamp":1580517103000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12098-018-02854-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,1]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["2854"],"URL":"https:\/\/doi.org\/10.1007\/s12098-018-02854-8","relation":{},"ISSN":["0019-5456","0973-7693"],"issn-type":[{"value":"0019-5456","type":"print"},{"value":"0973-7693","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,1]]},"assertion":[{"value":"7 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Source of Funding"}}]}}